Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to $36.6 million.

  • Neuphoria Therapeutics' Liabilities and Shareholders Equity rose 10144.13% to $36.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $123.2 million, marking a year-over-year increase of 569.26%. This contributed to the annual value of $28.6 million for FY2025, which is N/A changed from last year.
  • Per Neuphoria Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $36.6 million for Q4 2025, which was up 10144.13% from $27.3 million recorded in Q3 2025.
  • In the past 5 years, Neuphoria Therapeutics' Liabilities and Shareholders Equity registered a high of $49.4 million during Q4 2021, and its lowest value of $18.2 million during Q4 2024.
  • Over the past 5 years, Neuphoria Therapeutics' median Liabilities and Shareholders Equity value was $28.7 million (recorded in 2023), while the average stood at $32.1 million.
  • Per our database at Business Quant, Neuphoria Therapeutics' Liabilities and Shareholders Equity crashed by 3855.85% in 2023 and then surged by 10144.13% in 2025.
  • Quarter analysis of 5 years shows Neuphoria Therapeutics' Liabilities and Shareholders Equity stood at $49.4 million in 2021, then fell by 5.35% to $46.8 million in 2022, then plummeted by 38.56% to $28.7 million in 2023, then plummeted by 36.79% to $18.2 million in 2024, then surged by 101.44% to $36.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $36.6 million in Q4 2025, compared to $27.3 million in Q3 2025 and $28.6 million in Q2 2025.